Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Raw Materials (2022 - 2024)

Atara Biotherapeutics (ATRA) has disclosed Raw Materials for 3 consecutive years, with $964000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Raw Materials fell 58.72% year-over-year to $964000.0, compared with a TTM value of $964000.0 through Dec 2024, down 58.72%, and an annual FY2024 reading of $964000.0, down 58.72% over the prior year.
  • Raw Materials was $964000.0 for Q4 2024 at Atara Biotherapeutics, down from $1.7 million in the prior quarter.
  • Across five years, Raw Materials topped out at $4.4 million in Q1 2024 and bottomed at $964000.0 in Q4 2024.
  • Average Raw Materials over 3 years is $2.3 million, with a median of $2.3 million recorded in 2023.
  • Peak annual rise in Raw Materials hit 229.38% in 2024, while the deepest fall reached 58.72% in 2024.
  • Year by year, Raw Materials stood at $1.2 million in 2022, then skyrocketed by 92.34% to $2.3 million in 2023, then crashed by 58.72% to $964000.0 in 2024.
  • Business Quant data shows Raw Materials for ATRA at $964000.0 in Q4 2024, $1.7 million in Q3 2024, and $3.6 million in Q2 2024.